Estrogen Receptor Binding Site Associated Antigen 9 Human Recombinant

Product overview
Catalog Number
PPH08-0437
Sequence
MGSSHHHHHH SSGLVPRGSH MRSGRGRKLS GDQITLPTTV DYSSVPKQTD VEEWTSWDED APTSVKIEGG NGNVATQQNS LEQLEPDYFK DMTPTIRKTQ KIVIKKREPL NFGIPDGSTG FSSRLAATQD LPFIHQSSEL GDLDTWQENT NAWEEEEDAA WQAEEVLRQQ KLADREKRAA EQQRKKMEKE AQRLMKKEQN KIGVKLS
Target
EBAG9 promotes progression of bladder cancer. In rheumatoid arthritis, the deficiency of EBAG9 induces CTL infiltration through failure to evade immune attack, therefore leading to apoptosis of the synovial lining cells. EBAG9 is involved in controlling e
Description
EBAG9 is a type III transmembrane protein that is primarily located in the Golgi. EBAG9 is a tumor-associated antigen that is expressed at high frequency in a variety of cancers, such as advanced breast and prostate cancers. While EBAG9 acts to inhibit the growth of receptor-binding cells and induced apoptosis of immune cells, cancer cells may evade immune surveillance. Thus immunodetection of EBAG9 expression can be a negative prognostic indicator.
Category
Catalog peptides, Biologically Active Peptides
Product Properties
Quantity

10µg, 50µg, 1000µg
Storage

Shipped at 4°C. Store at -20°C for one year.
Purity

> 95%
Source

Synthetic
Forma appearance

Lyophilized powder
  • For research use only
  • Not for use in diagnostic procedures

€30,00 – €1.780,00 Tax excluded
Contact us to request price here
Register to buy peptides
Contact us